Narinder Janghra

754 citations
14 papers · 461 · h-index 7

Impact in

  • Genetics top 5%
    • Neurogenetic and Muscular Disorders Research
  • Oncology
    • CAR-T cell therapy research
    • HER2/EGFR in Cancer Research

Papers in

  • Molecular Biology 9
    • Cancer therapeutics and mechanisms 3
    • RNA modifications and cancer 2
    • Muscle Physiology and Disorders 2
  • Oncology 9
    • HER2/EGFR in Cancer Research 5
    • CAR-T cell therapy research 5
Co-authors
Jennifer E. Morgan (4 shared papers)Francesco Muntoni (3 shared papers)Haiyan Zhou (2 shared papers)Francesca Zammarchi (8 shared papers)Patrick H. van Berkel (8 shared papers)Philip W. Howard (3 shared papers)John A. Hartley (6 shared papers)David G. Williams (5 shared papers)
Journals
Cancer Research (5 papers)Molecular Cancer Therapeutics (2 papers)Blood (2 papers)Human Gene Therapy (1 paper)Human Molecular Genetics (1 paper)
Partner nations
United KingdomNetherlandsSwitzerland

In The Last Decade

Narinder Janghra

13 papers receiving 445 citations

Peers

Narinder Janghra
Comparison fields: 5 of 41
  • Genetics 160
  • Oncology 192
  • Pathology and Forensic Medicine 75
  • Radiology, Nuclear Medicine and Imaging 95
  • Molecular Biology 257
Replace В. Е. Парфенов with:
В. Е. Парфенов Germany
Sylvia C. Kurz United States
Chia‐Ing Jan Taiwan
Stephan Garbe Germany
Thomas Linsenmann Germany
Shaio Woo United States
James N. Gerson United States
Tingxun Lu China
Zhiyong Qin China
Yoshinori Tanizaki Japan
Narinder Janghra relative to В. Е. Парфенов Germany В. Е. Парфенов's profile →
Citations per field
00.5×2×3.0×
В. Е. Парфенов · 1×
Citations per year

Countries citing papers authored by Narinder Janghra

Since Specialization
Citations

This map shows the geographic impact of Narinder Janghra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narinder Janghra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narinder Janghra more than expected).

Fields of papers citing papers by Narinder Janghra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narinder Janghra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narinder Janghra. The network helps show where Narinder Janghra may publish in the future.

Co-authors

The 25 scholars most cited alongside Narinder Janghra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Narinder Janghra Line = papers co-authored together Narinder Janghra links everyone, so they are left out of the graph.

All Works

14 of 14 papers shown
#Work
1
ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
Blood ·Francesca Zammarchi, Simon Corbett, Lauren Adams, Peter Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E. Britten, Carin E.G. Havenith, Simon Chivers, François D’Hooge, David G. Williams, Arnaud Tiberghien, Philip W. Howard, John A. Hartley, Patrick H. van Berkel
2018118
2
A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe Spinal Muscular Atrophy Transgenic Mice
Human Gene Therapy ·Haiyan Zhou, Narinder Janghra, Chalermchai Mitrpant, Rachel L. Dickinson, Karen Anthony, Loren Price, Ian C. Eperon, Steve D. Wilton, Jennifer E. Morgan, Francesco Muntoni
2013100
3
ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Molecular Cancer Therapeutics ·Michael Flynn, Francesca Zammarchi, Peter Tyrer, Ayse U. Akarca, Narinder Janghra, Charles E. Britten, Carin E.G. Havenith, Jean-Noel Levy, Arnaud Tiberghien, Luke A. Masterson, Conor S. Barry, François D’Hooge, Teresa Marafioti, Paul W.H.I. Parren, David G. Williams, Philip W. Howard, Patrick H. van Berkel, John A. Hartley
201685
4
Biochemical Characterization of Patients With In-Frame or Out-of-FrameDMDDeletions Pertinent to Exon 44 or 45 Skipping
JAMA Neurology ·Karen Anthony, Virginia Arechavala‐Gomeza, Valeria Ricotti, Silvia Torelli, Lucy Feng, Narinder Janghra, Giorgio Tasca, Michela Guglieri, Rita Barresi, Annarita Armaroli, Alessandra Ferlini, K. Bushby, Volker Straub, Enzo Ricci, Caroline A. Sewry, Jennifer E. Morgan, Francesco Muntoni
201358
5
Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response
Human Molecular Genetics ·Haiyan Zhou, Jinhong Meng, Elena Marrosu, Narinder Janghra, Jennifer E. Morgan, Francesco Muntoni
201543
6
Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies
PLoS ONE ·Narinder Janghra, Jennifer E. Morgan, Caroline A. Sewry, Francis X. Wilson, Kay E. Davies, Francesco Muntoni, Jonathon M. Tinsley
201634
7
ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Molecular Cancer Therapeutics ·Francesca Zammarchi, Karin Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, François Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A. Hartley, Patrick H. van Berkel
20246
8
Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Blood ·Michael Flynn, Patrick H. van Berkel, Francesca Zammarchi, Peter Tyrer, Ayse U. Akarca, Narinder Janghra, Vishvesh Shende, J. Linares, Teresa Marafioti, David G. Williams, Philip W. Howard, John A. Hartley
20156
9
Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors
Cancer Research ·Francesca Zammarchi, Halla W. Reinert, Narinder Janghra, Simon Corbett, Maria Mellinas‐Gomez, Sajidah Chowdhury, Neha Arora, Peter Tyrer, François Bertelli, David G. Williams, Philip W. Howard, John A. Hartley, Patrick H. van Berkel
20174
10
Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6
Cancer Research ·Nicola Tsang, Nicolas Veillard, Elizabeth Horsley, Karin Havenith, Narinder Janghra, Kristina Zaitseva, Cecile Oblette, Ian Kirby, Paul W. Hogg, Francesca Zammarchi, Lolke de Haan, Patrick H. van Berkel
20242
11
Abnormalities of the cadherin–catenin complex in chemically-induced colo-rectal carcinogenesis
Proceedings of The Nutrition Society ·Elizabeth R. Tucker, Andrea Buda, Narinder Janghra, Jennifer H.E. Baker, James E. Coad, Morganden Moorghan, M. E. Havler, Peter W. Dettmar, Massimo Pignatelli
20032
12
Abstract 51: Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies
Cancer Research ·Francesca Zammarchi, Simon Corbett, Karin Havenith, Narinder Janghra, Konstantinos Kiakos, Teresa Marafioti, David G. Williams, Simon Chivers, Phil W. Howard, John A. Hartley, Patrick H. van Berkel
20171
13
Abstract 5085: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b
Cancer Research ·Elizabeth Horsley, Asma Jabeen, Nicolas Veillard, Karin Havenith, Narinder Janghra, Pedro Alves, Cecile Oblette, Ian Kirby, Paul W. Hogg, Francesca Zammarchi, Lolke de Haan, Patrick van Berkel
20241
14
Abstract 1580: HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers
Cancer Research ·Danilo Cucchi, Elizabeth Horsley, Alina Chrzastek, Ben Leatherdale, Simone Sims, Nicole Bledowski, Banusha Rajeenthira, Narinder Janghra, Lara Montolio, Abigail Kimpalu, Christopher M. Gallagher, Charlie Britten, Lolke de Haan, Paul W. Hogg, Chris Pickford, Patrick H. van Berkel
20251

About Narinder Janghra

Narinder Janghra is a scholar working on Molecular Biology, Oncology, Pathology and Forensic Medicine, Genetics and Organic Chemistry, having authored 14 papers that have together received 461 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (5 papers), CAR-T cell therapy research (5 papers), Cancer therapeutics and mechanisms (3 papers), Lymphoma Diagnosis and Treatment (2 papers), Synthesis and pharmacology of benzodiazepine derivatives (2 papers), RNA modifications and cancer (2 papers), Neurogenetic and Muscular Disorders Research (2 papers) and Muscle Physiology and Disorders (2 papers). The work is most often cited by research in Genetics (160 citations), Oncology (192 citations), Pathology and Forensic Medicine (75 citations), Radiology, Nuclear Medicine and Imaging (95 citations) and Molecular Biology (257 citations). Narinder Janghra has collaborated with scholars based in United Kingdom, Netherlands and Switzerland. Frequent co-authors include Jennifer E. Morgan, Francesco Muntoni, Haiyan Zhou, Francesca Zammarchi, Patrick H. van Berkel, Philip W. Howard, John A. Hartley, David G. Williams, Teresa Marafioti and Karen Anthony. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Blood, Human Gene Therapy and Human Molecular Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by В. Е. ПарфеновBreakdown of academic impact, for papers by Sylvia C. KurzBreakdown of academic impact, for papers by Chia‐Ing JanBreakdown of academic impact, for papers by Stephan GarbeBreakdown of academic impact, for papers by Thomas LinsenmannBreakdown of academic impact, for papers by Shaio WooBreakdown of academic impact, for papers by James N. GersonBreakdown of academic impact, for papers by Tingxun LuBreakdown of academic impact, for papers by Zhiyong QinBreakdown of academic impact, for papers by Yoshinori Tanizaki